NOI - B2B Award entitled - Developing Red Cell-Sp

This NIH Notice of Intent awards a non‑competitive, single‑source contract to Purdue University for medicinal‑chemistry services focused on synthesis, scale‑up, and characterization of lead Spleen Tyrosine Kinase (SYK) inhibitors (S1115 and S1213) to support a Bench‑to‑Bedside sickle‑cell disease study. The work includes producing 3–5 g of each compound, delivering analytical data, and providing related assay and optimization services over a 12‑month period. • Scope: Chemical synthesis, scale‑up, analytical characterization, and related research‑support services for SYK inhibitor candidates. • Location: Work performed at Purdue University, West Lafayette, IN; final deliverables shipped to NIH, Bethesda, MD. • Timeline: Quote due by November 4, 2026 (13:00 EDT); performance period November 6 2026 – November 5 2027. • Funding: No dollar amount disclosed; typical medicinal‑chemistry service contracts of this scale range from several hundred thousand to over a million dollars. • Eligibility: Must be capable of medicinal‑chemistry scale‑up, have SAM registration, and possess UEI/TIN.